COMPASS Pathways - American Depository Shares Stock 12‑Month Price Target Cut to $23.18, Implies 176% Upside
Analysts' average price target for COMPASS Pathways ADS fell slightly from $23.35 to $23.18, with a range of $10 to $65. This implies a 176% upside from the Nov. 2 closing price. The consensus rating remains 'Buy' among 18 analysts.
How this was made
The 30-second read
Why it matters
Analyst target cuts can prompt short‑term price declines, but the wide target range suggests continued volatility.
Market read
The price‑target cut is a modest, company‑specific update with limited broader market impact.
What to watch
The target range still spans $10‑$65, indicating high uncertainty and possible upside beyond the average.
Background
The article reports a consensus analyst price‑target revision for COMPASS Pathways, a biotech focused on psychedelic therapies.
Ticker impact
Analysts cut the average 12‑month price target for COMPASS Pathways to $23.18, down from $23.35.
likely downside pressure as the market prices in the lower target
A price‑target cut signals analysts see weaker prospects, which typically drags the share price.
Market effects
Minimal; the change is specific to COMPASS Pathways and does not materially affect the broader biotech sector.
None; the news is company‑specific.
Low; limited to investors tracking this micro‑cap.
Counterpoint
Some investors may view the modest cut as an opportunity if they believe the upside potential remains large.
Key entities
- companyCOMPASS Pathways Plc
Biotech company developing psychedelic medicines.
